Jazieh Khalid, Bell Ruth, Agarwal Nayan, Abraham Jame
Department of Internal Medicine, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Department of Solid Tumor Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Ann Transl Med. 2020 Jul;8(14):907. doi: 10.21037/atm.2020.03.43.
Metastatic breast cancer (mBC) continues to be a leading cause of cancer-related death in women. Even though mortality rates have improved over recent years, the 5-year survival rate of advanced BC is still at only 27%. As researchers and clinicians attempt to tackle this challenge, there has been extensive research and many trials studying treatment options for BC patients with metastatic disease, with numerous new therapies being discovered as a result. We review the most pertinent novel agents to enter the scope of BC treatment, including CDK4/6 inhibitors, PI3K inhibitors, mTOR inhibitors, immunotherapy, PARP inhibitors, and more.
转移性乳腺癌（mBC）仍然是女性癌症相关死亡的主要原因。尽管近年来死亡率有所改善，但晚期乳腺癌的5年生存率仍仅为27%。随着研究人员和临床医生试图应对这一挑战，针对转移性疾病的乳腺癌患者的治疗选择进行了广泛的研究和许多试验，结果发现了许多新疗法。我们回顾了进入乳腺癌治疗范围的最相关新型药物，包括细胞周期蛋白依赖性激酶4/6（CDK4/6）抑制剂、磷脂酰肌醇-3激酶（PI3K）抑制剂、哺乳动物雷帕霉素靶蛋白（mTOR）抑制剂、免疫疗法、聚（ADP-核糖）聚合酶（PARP）抑制剂等。
